The National Institutes of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in July 2025. This award will support the application of Tango Biosciences’ proprietary Avidimer platform for the development of protein tools that enhance the discovery of proximity inducing modalities such as molecular glues. The Avidimers developed in this program will generate proof-of-concept data for driving proximity of two protein targets resulting in a highly sensitive assay readout. Such tools may lead to the identification of new drugs for targeted protein degradation and beyond.
NIH Awards New SBIR Grant
More News and Events
-
New Phase II SBIR Grant
Tango Biosciences has been awarded a phase II SBIR grant by the National Institutes of Health (NIH) in September 2026. This award will support the continued development of Tango Biosciences’ phage display platform to discover phosphobodies, antibody-like molecules that recognize distinct phosphorylated targets with unprecedented precision and specificity. The platform and affinity reagents generated in […]
-
News
NIH Awards New Phase I SBIR Grant
The National Institute of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in August 2026. This award will support the development of Tango Biosciences’ phage display platform to identify peptide tools that act as proximity inducing modalities (e.g., molecular glues). The program will generate proof-of-concept data for driving proximity of two protein […]
-
Tango Biosciences Celebrates 10 Years of Discovery
This year Tango Biosciences celebrates their ten-year anniversary, a milestone that resonates with scientific innovation and a sustained commitment to solving complex challenges in drug discovery and diagnostics. Visionary founders Dr. Brian Kay and Michael Scholle recently sat down to take a deep dive into the company’s incredible journey. They revealed an origin story that perfectly […]